Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NEC OncoImmunity
Oslo, Norwaynec-bio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
NEC OncoImmunity’s technology has demonstrated that high-quality neoantigen prediction correlates with improved progression-free survival in sarcoma patients treated with checkpoint inhibitors. Clinical trials are ongoing for personalized cancer vaccines such as TG4050 targeting ovarian and head & neck cancers. The company also develops broadly protective vaccine designs against infectious diseases using its AI platform
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Personalized cancer vaccinesAI-designed peptide vaccinesimmunotherapies
- Industry
- Biotech
02
Partnerships
Transgene SA—collaboration on TG4050 personalized immunotherapy clinical trialsCEPI—collaboration/funding for broadly protective coronavirus vaccines developmentNagasaki University—research collaboration on tropical diseases funded by SCARDABostonGene—strategic investment partnership focused on advanced patient analysis for optimal therapy selection
Beyond the preview
Go deeper on NEC OncoImmunity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEC OncoImmunity.